Français
ItalianoBond Eli Lilly & Company 6.57% ( US532457AN86 ) in USD
| Issuer | Eli Lilly & Company |
| Market price | 100 % ⇌ |
| Country |  United States
|
| ISIN code |
 US532457AN86 ( in USD )
|
| Interest rate | 6.57% per year ( payment 2 times a year) |
| Maturity | 01/01/2016 - Bond has expired |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 1 000 USD |
| Total amount | 200 000 000 USD |
| Cusip | 532457AN8 |
| Standard & Poor's ( S&P ) rating | AA- ( High grade - Investment-grade ) |
| Moody's rating | NR |
| Detailed description |
Eli Lilly and Company is a global pharmaceutical company specializing in the research, development, manufacturing, and marketing of pharmaceutical products and biologicals. This financial article provides an overview of a specific fixed-income instrument issued by Eli Lilly, a prominent global pharmaceutical company headquartered in the United States, well-regarded for its extensive research, development, manufacturing, and marketing of pharmaceutical products worldwide. The bond, uniquely identified by ISIN US532457AN86 and CUSIP 532457AN8, was denominated in U.S. Dollars (USD) and carried a fixed interest rate of 6.57%. This particular issuance had a total size of $200,000,000, with a minimum purchase amount set at $1,000, making it accessible for varying investor scales. Interest payments were structured on a semi-annual basis, corresponding to the stated payment frequency of two times per year. Notably, this bond reached its full maturity on January 1, 2016, and was subsequently repaid to bondholders at 100% of its face value, confirming the fulfillment of the issuer's obligations. Throughout its lifecycle, the bond benefited from strong credit assessments for Eli Lilly, most notably an 'AA-' rating from Standard & Poor's (S&P), signifying a very strong capacity to meet its financial commitments; it was designated 'NR' (Not Rated) by Moody's. |